Author

Amy Bobbins

Institutions: Drug Safety Research Unit, UK Health Security Agency, University of Portsmouth

Observed institutions: Drug Safety Research Unit, UK Health Security Agency, University of Portsmouth

ORCID: 0000-0001-7587-4130

Observed ORCID: 0000-0001-7587-4130

OpenAlex ID: A5094114080

Safety and effectiveness of the anti‐amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective

2025 · Amy Bobbins, Miranda Davies, et al. · British Journal of Clinical Pharmacology · 29

A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements

2026 · Dawn Cooper, Mohammed Toseef Ansari, et al. · Drug Safety · 2

Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group

2026 · Florence van Hunsel, Samantha Lane, et al. · Drug Safety · 1

Mapping the Evidence for Oropouche Virus to Inform Research Prioritisation

2026 · Sowsan F. Atabani, Matthew Bosworth, et al. · Reviews in Medical Virology

The public health impact of suspending cyproterone acetate/ ethinylestradiol (Diane-35 and generics) in France: A predictive modelling technique

2024 · Samantha Lane, Elizabeth Lynn, et al.

Works count: 5

Citation count: 32

H-index: 2

I10-index: 1